Overview

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Nintedanib
Paclitaxel